Almirall, Microsoft partner to develop novel treatments for skin diseases
The three-year collaboration is aimed at advancing the digitalisation and technology to advance medical dermatology and develop next-generation…
We use them to give you the best experience. If you continue using our website, we'll assume that you are happy to receive all cookies on this website.
ContinueLearn More X
01 Feb 24
The three-year collaboration is aimed at advancing the digitalisation and technology to advance medical dermatology and develop next-generation…
01 Feb 24
The company will return the licensing rights of the drug and terminate its post-marketing confirmatory ENVISION trial after…
01 Feb 24
Tyruko biosimilar to treat adults with highly active relapsing remitting multiple sclerosis (RRMS)
01 Feb 24
Designation is based on preliminary safety and efficacy data from an ongoing Phase 1/2 trial in patients with…
31 Jan 24
Astellas seeks approval from Japan's MHLW for the combination therapy to treat adult patients with previously untreated locally…
30 Jan 24
Produced in the U.S., the generic anti-fungal drug is fully substitutable for Noxafil
29 Jan 24
Pfizer and Astellas Pharma seek approval for Padcev with Keytruda as the first-line treatment of adult patients with…
29 Jan 24
The CheckMate -67T trial showed that the subcutaneous nivolumab demonstrated noninferior pharmacokinetics and objective response rate compared to…
29 Jan 24
Rain Stockholders to Receive $1.16 Per Share in Cash Plus Contingent Value Rights
29 Jan 24
The new presentation of Mounjaro gives four doses for once-a-week treatment over a month